Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Cardioblate CryoFlex Surgical Ablation System in Longstanding Persistent Atrial Fibrillation

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have a documented history of longstanding persistent AF as defined by the HRS/EHRA/ECAS Guidelines~* Patients should have a concomitant indication (other than AF) for open-heart surgery for mitral valve repair or replacement (bioprosthesis)~* Patients should be older than or equal to 18 years of age~Exclusion Criteria:~* Atrioventricular reentrant tachycardia (AVRT)~* NYHA Class = IV~* Left ejection fraction of ≤ 30%~* Need for emergent cardiac surgery (i.e. cardiogenic shock) or redo open heart surgery~* Previous atrial fibrillation ablation, AV-nodal ablation, or surgical Maze procedure~* Contraindication for anticoagulation therapy~* Left atrial diameter \> 7.0 cm~* Preoperative need for intra-aortic balloon pump or intravenous inotropes~* Renal failure requiring dialysis or hepatic failure~* Life expectancy of less than one year~* Pregnancy or desire to be pregnant within 12 months of the study treatment~* Current diagnosis of active systemic infection~* Documented MI 6 weeks prior to study enrollment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cardioblate CryoFlex Surgical Ablation (Type: EXPERIMENTAL): Subjects with longstanding persistent AF undergoing Maze III procedure using the Cardioblate CryoFlex Surgical Ablation System concomittant to Mitral valve surgery. During surgery, a Medtronic Reveal XT Insertable Cardiac Monitor was implanted to monitor future episodes of AF.

Based on this trial design, predict the completion outcome and termination type (if applicable).